Tenaya Therapeutics Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 16.9% | – | – | – | – | – | – | – | – | 783.6% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -16.9% | – | – | – | – | – | – | – | – | -683.6% | 100.0% | 124.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 129.4% | – | – | – | – | – | – | – | – | 6,596.9% | 1,495.8% | 4,614.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 48.6% | – | – | – | – | – | – | – | – | 2,420.9% | 487.0% | 1,678.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 161.1% | – | – | – | – | – | – | – | – | 8,234.2% | 4,071.9% | 8,193.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -178.0% | – | – | – | – | – | – | – | – | -8,917.8% | -3,971.9% | -7,929.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -169.5% | – | – | – | – | – | – | – | – | -8,565.3% | -3,909.3% | -7,724.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 16.7% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -169.5% | – | – | – | – | – | – | – | – | -8,565.3% | -3,909.3% | -7,724.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -152.6% | – | – | – | – | – | – | – | – | -7,781.8% | -3,756.1% | -7,188.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.